Skip to main content

Table 4 Comparison of intervention and placebo groups in terms of side effects

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

  Univariable Multivariable
No Yes OR (95% CI) P-value OR (95% CI) P-value
Group
 Active 23 (69.7%) 10 (30.3%) 1.81 (0.57,5.78) 0.315 1.97 (0.58,6.69) 0.279
 Placebo 25 (80.6%) 6 (19.4%) Reference Reference
Sex
 Female 34 (79.1%) 9 (20.9%) Reference 0.286 Reference 0.155
 Male 14 (66.7%) 7 (33.7%) 1.89 (0.59,6.07) 2.81 (0.68,11.65)
Marital Status
 Single 17 (70.8%) 7 (29.2%) 1.42 (0.45,4.86) 0.552 0.48 (0.18,3.99) 0.823
 Married 31 (77.5%) 9 (22.5%) Reference Reference
Duration of Migraine
 ≤2 years 26 (72.2%) 10 (27.8%) 1.41 (0.44,4.50) 0.562 0.94 (0.25,3.51) 0.992
 > 2 years 22 (78.6%) 6 (21.4%) Reference Reference
Age (mean ± SD) 37.29 ± 9.42 33.81 ± 8.89 0.96 (0.89,1.02) 0.20 0.97 (0.87,1.07) 0.494
BMI (mean ± SD) 24.25 ± 3.03 23.14 ± 2.99 0.88 (0.72,1.08) 0.21 0.88 (0.68,1.16) 0.369
  1. BMI Body–mass index, SD Standard deviation, CI Confidence interval